World’s First Nanosecond PFA System Received NMPA Approval

On June 27, China’s National Medical Products Administration (NMPA) officially approved the market launch of the NxPFA® cardiac nanosecond pulsed field ablation system, developed by Pulsecare Medical. As the world’s first atrial fibrillation (AFib) treatment device to use high-voltage pulsed field technology with a nanosecond pulse width, this system represents a historic leap for China.

Technological Revolution: From ‘Thermal Injury’ to ‘Electroporation’ for a Leap in Precision Therapy

Traditional AFib ablation techniques use radiofrequency or cryoenergy to destroy myocardial tissue with high or low temperatures. This often causes collateral damage, leading to complications like esophageal injury and phrenic nerve paralysis at high rates.

Pulsecare Medical’s pioneering NxPFA® system uses nanosecond-level high-voltage pulsed fields (50 ns – 1 μs) to precisely ablate abnormal myocardial cells through irreversible electroporation (IRE). This breakthrough offers three key advantages:

• More Precise: The electric field energy precisely targets myocardial cell membranes, avoiding accidental damage to adjacent tissues like blood vessels and nerves.
• Safer: Real-time monitoring of tissue impedance during the procedure allows for dynamic energy adjustments, preventing over-ablation.
• More Comfortable: The system’s significantly reduced neuromuscular stimulation allows 92.8% of procedures to be performed with pain relief and local anesthesia, with patients remaining fully conscious.

Disclaimer: The information on this platform is for informational purposes only and is based on publicly available sources, such as official press releases and regulatory databases. While we strive for accuracy, details may vary from the manufacturer’s official statements, particularly if they have been translated. We encourage readers to consult the manufacturer’s official website and communications for the most current and accurate information. This report is not a substitute for professional medical advice, diagnosis, or treatment and does not constitute an endorsement of any product or company. We do not accept responsibility for any errors, omissions, or actions taken based on the information provided.